Stock KTRA KINTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Kintara Therapeutics, Inc.

Equities

KTRA

US49720K2006

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/06/2024 BST 		5-day change 1st Jan Change
0.3269 USD +9.55% Intraday chart for Kintara Therapeutics, Inc. +51.34% +92.75%
06-03 TuHura Biosciences, Inc. and Kintara Therapeutics, Inc. Announces Positive Results from Phase 1b Trial of IFx-2.0 CI
05-14 Kintara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kintara Therapeutics, Inc. Announces Executive Changes
CI
Saiid Zarrabian to Step Down from His Role as Head of Strategic Partnerships and as A Member of the Board of Kintara Therapeutics
CI
Kintara Therapeutics, Inc. Announces Resignation of Keith Murphy from the Board of Directors
CI
Kintara Therapeutics Names Robert E. Hoffman as CEO
MT
Kintara Announces Executive Changes
CI
Kintara Therapeutics Announces Management Changes
CI
Kintara Therapeutics, Inc. Announces That John Liatos Decides to Step Down as Senior Vice President, Business Development Effective Immediately
CI
Kintara Therapeutics, Inc. Announces Board Changes
CI
Kintara Therapeutics, Inc. Appoints Mario Lacouture to the REM-001 Scientific Advisory Board
CI
Kintara Therapeutics Announces Board Appointments
CI
DelMar Pharmaceuticals, Inc. Approves the Election of Laura Johnson as Director
CI
Delmar Pharmaceuticals, Inc. and Adgero Biopharmaceuticals Holdings, Inc. Announce Combined Company Management Appointments
CI
DelMar Pharmaceuticals, Inc. Announces Scientific Advisory Board Appointments
CI
DelMar Pharmaceuticals, Inc. Announces the Formation of Scientific Advisory Board
CI
DelMar Pharmaceuticals Appoints Napoleone Ferrara to Board of Directors
CI
DelMar Pharmaceuticals, Inc. Announces Board Changes
CI
DelMar Appoints Saiid Zarrabian to Full-Time President and CEO
CI
Delmar Pharmaceuticals, Inc. Announces the Resignation of Jeffrey Bacha as a President and Chief Operating Officer, Effective January 1, 2018
CI
Delmar Pharmaceuticals, Inc. Announces Executive Changes, Effective November 3, 2017
CI
DelMar Pharmaceuticals, Inc. Announces Executive Appointments
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KTRA Stock
  4. News Kintara Therapeutics, Inc.
  5. Insiders